BNP Paribas Asset Management
ADPT icon

BNP Paribas Asset Management’s Adaptive Biotechnologies ADPT Stock Holding History

BNP Paribas Asset Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.8M Sell
2,182,326
-505,755
-19% -$7.75M 0.05% 358
2026
Q1 		$37.3M Buy
+2,688,081
New +$42.8M 0.04% 393

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

BNP Paribas Asset Management's ADPT Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Adaptive Biotechnologies (ADPT) stake by 19% in Q2 2026, selling an estimated $7.75M and leaving 2,182,326 shares worth $46.8M. The position accounts for 0.05% of the portfolio, ranked #358.

BNP Paribas Asset Management first reported a position in ADPT in Q1 2026 and has held it in 2 quarters since. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • BNP Paribas Asset Management held 2,182,326 shares of Adaptive Biotechnologies worth $46.8M as of Q2 2026.
  • BNP Paribas Asset Management sold 505,755 Adaptive Biotechnologies shares in Q2 2026, an estimated $7.75M.
  • Adaptive Biotechnologies made up 0.05% of BNP Paribas Asset Management's portfolio in Q2 2026, its #358 holding.
  • BNP Paribas Asset Management first reported a position in Adaptive Biotechnologies in Q1 2026 and has held it in 2 quarters since.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.